Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Takayasu Arteritis Therapy
Investigators at University of East Anglia have published new data on takayasu arteritis therapy
July 27th, 2009
Researchers detail in 'The epidemiology of Takayasu arteritis in the UK,' new data in takayasu arteritis. "Takayasu arteritis (TAK) is a large-vessel vasculitis of unknown aetiology. The annual incidence in hospital-based studies is 1-2/million," scientists writing in the journal Rheumatology report. "The UK General Practice Research Database (UKGPRD) contains complete primary care records on 3.6 million people. There are no data on the incidence of TAK in the UK or from primary care anywhere in the world. The aim of this study was to determine the annual incidence of TAK in the UK using the UKGPRD and in a well-defined hospital population [Norfolk Vasculitis...
Source: Biotech Business Week (2009-07-27)
|
